Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with... Read More

Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting... Read More

Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and... Read More

First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc , (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preliminary results from its first three single... Read More

Data to be presented at the 8 th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio , a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and... Read More

Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic disease, today announced that it has... Read More

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic... Read More

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it dosed its first subject in its Phase 1 clinical study of PALI-2108, an orally administered PDE4 inhibitor prodrug that... Read More

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio,... Read More

Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at ACG’s 2024 Annual Scientific Meeting being held October 25-30,... Read More

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) and food effects (FE) and includes multiple dose treatment of UC patients; Global UC market is expected to grow to nearly $10 Billion by 2028 Carlsbad, CA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio,... Read More

Live webcast fireside chat on Tuesday, October 15 th at 4:30 PM ET Carlsbad, CA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that J.D. Finley, Chief Executive Officer and Dr. Mitch... Read More

Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose Completion of pre- Clinical Trial Application (CTA) meeting with Health Canada Submission of the CTA for the Phase 1 clinical study of Normal Healthy Volunteers and ulcerative colitis patients On track towards clinical site initiation and dosing of first patient in Phase 1 human clinical... Read More

Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases Successful completion of nonclinical safety and toxicity studies and continued execution of regulatory requirements towards launch of Phase 1 human clinical study for lead program, PALI-2108 for the treatment of UC before year end Carlsbad, CA, Sept. 16, 2024 (GLOBE... Read More

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program PALI-2108, an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients affected by Ulcerative Colitis (UC) Phase 1 human clinical study of PALI-2108 for the treatment of UC on track to commence... Read More

Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended. The Company’s Compensation... Read More

Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end Company continues to establish growing body of preclinical data for PALI-2108 and global patent estate Sufficient cash on hand to execute on current business plan and reach clinical and regulatory milestones through first quarter of 2025 Carlsbad, CA, Aug.... Read More

Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end Based on the modeling and simulations, Palisade has established dose levels and trial design for PALI-2108 Carlsbad, CA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc . (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing... Read More

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108 Carlsbad, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today... Read More

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, July 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing... Read More

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in... Read More

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024... Read More

Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday,... Read More

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living... Read More

Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00... Read More

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative... Read More

Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end Sufficient cash on hand to execute on business plan and reach clinical and regulatory milestones into 2025 Carlsbad, CA, May 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused... Read More

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,... Read More

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded... Read More

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered into a definitive agreement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu... Read More

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced... Read More

Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company... Read More

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion... Read More

Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the... Read More

PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic... Read More

Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced a 1-for-15 reverse split of its common stock, par value $0.01 (“Common Stock”), effective at 5:00 PM ET on Friday April 5,... Read More

Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end Formation of Clinical Advisory Board Sufficient cash on hand to execute on business plan and achieve significant clinical milestones into 2025 Carlsbad, CA, March 27, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the... Read More

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024. The details of the poster presentation are as follows:... Read More

Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision Advancement of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study; first in human study on track to commence before year end Carlsbad, CA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a... Read More

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board... Read More

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health System Florian Rieder, MD, Associate Staff in the Department of Gastroenterology, Hepatology, and Nutrition, as well as an Investigator in the Department of Pathobiology at the Cleveland Clinic Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio,... Read More

Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the “Existing Warrants”) to purchase up to an aggregate of 3,413,286... Read More

Preclinical data demonstrated PALI-2108 to be safe and well tolerated PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure Company advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study, expected to commence in 2024 Carlsbad, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the... Read More

Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held January 25-27, 2024 in Las Vegas, NV. Details of the poster presentation... Read More

Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation Lead program, PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) advancing toward completion of IND-enabling studies with IND filing expected by Q3 2024 Carlsbad, CA, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)... Read More

Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anticipated to commence Phase 1 clinical study in 2024 Strong financial position with cash to execute on strategy and achieve significant milestones into 2025 Carlsbad, CA, Nov. 10, 2023 (GLOBE... Read More

Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will participate at the Virtual... Read More

Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32. Ladenburg Thalmann & Co.... Read More

Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven track record of... Read More

Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering. Ladenburg Thalmann... Read More

Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 Inflammatory bowel disease (IBD) represents a multi-billion dollar market opportunity with current therapies achieving a clinical remission rate of less than 20% on average Carlsbad, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)... Read More

Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline Strong financial position with cash to fund operations through 2024 Carlsbad, CA, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today... Read More

Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surger y Carlsbad, CA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported that the Company’s U.S. Phase 2 PROFILE study evaluating LB1148... Read More

Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the completion of patient enrollment in its dose optimization study of LB1148. “Achieving our enrollment target in this study is an important milestone for our LB1148... Read More

Live webcast fireside chat on Thursday, June 22 nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by... Read More

Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley has been named Chief Executive Officer (CEO), effective today. Mr. Finley has been serving as interim CEO since October 2022. “Since assuming the role of interim CEO, J.D. has... Read More

Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment complete Carlsbad, CA, May 24, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today... Read More

Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the first quarter 2023 and provided a corporate update. “We are looking forward to the upcoming... Read More

Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be completed in Q3 2023 Carlsbad, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today... Read More

Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 2,942,358 titled, “ Compositions for the Treatment of Autodigestion .” This key patent covers the composition of LB1148,... Read More

Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that its development partner Newsoara Biopharma Co. Ltd, has enrolled the first patient in its ongoing Phase 3 clinical trial in... Read More

Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,272,723 shares of common stock (or certain pre-funded warrants in lieu thereof) in a registered direct offering and... Read More

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 Carlsbad, CA, March 23, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its... Read More

Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that European Patent Office (EPO) has issued a notice of intention to grant for its patent application titled, “ Administration of Serine Protease Inhibitors to the Stomach.” Based on the... Read More

Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution Carlsbad, CA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the promotion of Robert McRae to Chief Operating Officer.... Read More

Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company”), today announced that holders of an additional 1.46 million common stock purchase warrants issued pursuant to the... Read More

Live video webcast on Tuesday, January 17 th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley, Interim Chief Executive Officer of Palisade Bio will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January... Read More

Carlsbad, CA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors for the purchase of 1,052,631 shares of common stock (or certain... Read More

Carlsbad, CA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 1,052,631 shares of common stock (or certain pre-funded warrants in lieu thereof) in a registered direct... Read More

Topline data readout from study expected in first half of 2023 Carlsbad, CA, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is providing an update on its U.S. Phase 2 study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection... Read More

Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time to the return of normal GI function Carlsbad, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announces the release of its new animated... Read More

Board Appoints JD Finley to Interim Chief Executive Officer Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced an executive leadership transition. Effective October 10, 2022, Thomas Hallam, Ph.D., ceased his duties as chief executive officer (CEO). The company’s board of directors has appointed JD Finley,... Read More

Palisade Bio , Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American College of Surgeons (ACS) Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA. Details of the abstract presentation are as follows: Session : Colon and Rectal Surgery I Title... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan. On August 29, 2022, the Company’s Compensation Committee granted options to two new non-executive employees covering an aggregate of 93,000 shares of the Company’s common... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will participate in a fireside chat on Thursday, September 29, 2022 at 11:30 AM ET at the Ladenburg Thalmann 2022 Healthcare Conference in New York, NY. In addition to the fireside chat,... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that following an internal strategic review, the Management Team and Board have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing the advancement of its lead clinical... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer and Michael Dawson, M.D., Chief Medical Officer of Palisade Bio will present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been dosed in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, commented, “The dosing of... Read More

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $13.8 million, prior to deducting underwriting discounts and commissions and offering expenses, including full exercise of the underwriter’s over-allotment... Read More

Palisade Bio (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company”), reported its financial results for the quarter ended June 30, 2022. Additionally, the Company provided a clinical program update for its lead asset in development, LB1148 , an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize... Read More

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of (i) 42,160,000 shares of common stock, (ii) 1,460 shares... Read More

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its new corporate website, palisadebio.com and reiterates its commitment to all stakeholders by developing therapeutics that protect intestinal barrier health. “As we advance the development of our lead product candidate, bolster our growing body... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been screened in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “The operational execution of our Phase 3 clinical development program for LB1148... Read More

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of normal GI function, and has the potential to prevent damage to GI tissues and shorten the duration of costly post-surgery hospital stays Phase 3 study design utilizes same dosing protocol and same primary endpoint as positive Phase 2... Read More

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will present on Monday, June 13, 2022 at 1:45 PM PT at the 2022 BIO International Convention being held in San Diego, CA. In addition to the presentation, management will be available to... Read More

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the quarter ended March 31, 2022.... Read More

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan. On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares of the Company’s common stock as an... Read More

Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55... Read More

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase 3 program in China Under the Co-Development Agreement, commencement of Phase 3 program in China will trigger milestone payment to Palisade Bio Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing... Read More

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its expected near-term pipeline advancements. “The positive data we have amassed continues to support our development strategy and provides us with confidence as we advance our lead program into a Phase 3 study this quarter. Each... Read More

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET. Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief Executive Officer, Michael... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that of Palisade Bio, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28–30, 2022. As part of the conference, a video webcast of the Company’s presentation will be available... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced that the Company received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery. The trial is... Read More

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic gastrointestinal (GI) complications, today provides a business update and reports its financial results for the year ended December 31, 2021. Highlights and Recent Events “This past year was a transformative year for Palisade Bio. In April, we... Read More

Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a... Read More

Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company's data being presented at the SAGES 2022 Annual Meeting and the need for new pharmaceutical options to prevent post-surgical abdominal adhesions. The live virtual event will begin Wednesday March... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at The Next Big Thing session of the Society of... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, will present at the Biocom Global Life Science Partnering Conference in San Diego on Thursday, February 24, 2022. Palisade Bio’s Chief Executive Officer, Tom Hallam, Ph.D., is scheduled to present an updated presentation at 11:30 a.m. Pacific Time. Palisade Bio’s... Read More

Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that Robert McRae has joined the senior management team as Senior Vice President, Operations and Strategic Development. Rob is an accomplished industry veteran with a proven track record of execution and will be responsible for internal operations helping... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN) has been selected for a presentation in The Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting.... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor meetings during that period... Read More

Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bio’s Patent Portfolio The Company Continues to Advance LB1148 for Key Indications After LB1148 Topline Efficacy Results from Phase 2 Trial Demonstrated Accelerated Return of Bowel Function Following Gastrointestinal Surgery Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic... Read More

Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the company will be granted a patent from the European Patent Office (EPO) covering its lead investigational drug product, LB1148. The patent will publish on December 22, 2021, and provide protection until 2035. “With the European patent grant, this... Read More

Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications (the “Company”), today announced that it had made equity grants to three new employees under its 2021 Inducement Plan (the “Plan”). “We are excited to add additional key members to our team to help us expand our clinical activities. Of particular... Read More

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the third quarter ended September 30, 2021. Third Quarter Highlights: In July 2021, the Company released top line Phase 2 clinical trial results... Read More

Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications, announces today that an early exercise option has led to the acquisition of the Seneca asset NSI-189, a neurogenic compound which was part of Seneca Biopharma’s product portfolio at the time of the merger to form Palisade Bio and which is part of the... Read More

Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces today that Chief Executive Officer Tom Hallam, Ph.D. will present at the H.C. Wainwright Global Investment Conference, which is being held virtually from September 13- 15, 2021. Dr. Hallam will deliver his corporate presentation, which will become available beginning on... Read More

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the second quarter ending June 30, 2021. Recent Corporate Highlights: Announced positive topline results from Phase 2 study of LB1148 by partner Newsoara demonstrating accelerated... Read More

$5.2M invested at $3.45 stock price Funds to be used to advance clinical development of LB1148 Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used as standard of care for the protection and healing of the GI tract in surgical patients if approved by the FDA Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a late‐stage biopharma company advancing... Read More

Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announced positive topline Phase 2 clinical trial data that LB1148 had a statistically significant (p=0.0008) effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery. “These... Read More

Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it entered into an exclusive license with the Regents of the University of California, expanding its proprietary technology for detecting enzymatic protease activity in human clinical samples. Under the terms of this agreement, in combination with a related 2020... Read More

Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its Clinical Steering Committee (CSC) designed to provide strategic guidance over late-stage clinical program development for its lead investigational drug, LB1148. The CSC will be chaired by retired board-certified-surgeon, Dr. David Berry, who... Read More

LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery A Phase 2 gastrointestinal surgery trial that will evaluate LB1148 for reduction in adhesions is expected to read out data in 2021 Palisade Bio, Inc. (Nasdaq: PALI), a late-stage biopharma company advancing therapies for acute... Read More

Palisade Bio, Inc. (Nasdaq: PALI), and co-development partner Newsoara today announce completion of a Phase 2 clinical trial evaluating lead drug candidate LB1148 for accelerating return of bowel function associated with gastrointestinal (GI) surgery. The PROFILE study in China is a randomized, double-blind, multicenter, Phase 2 trial that has enrolled over 120 patients undergoing elective bowel resection. Patients received... Read More

Palisade Bio, Inc. (Nasdaq: PALI), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it will host a key opinion leader (KOL) webinar event on LB1148, the Company’s lead asset for indications associated with GI Surgery, on Thursday, May 13, 2021 at 1:00pm Eastern Time. The webinar will feature presentations by KOLs Steven Wexner, M.D., Cleveland... Read More